![Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma](https://www.spandidos-publications.com/article_images/ijo/47/2/IJO-47-02-0583-g02.jpg)
Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma
![Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma - European Journal of Cancer Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma - European Journal of Cancer](https://www.ejcancer.com/cms/asset/6ba573ad-5c04-47ab-a66e-2ce078d37132/gr3.jpg)
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma - European Journal of Cancer
![Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ... Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...](https://www.thelancet.com/cms/attachment/d4b6735d-0b7a-48df-826e-512f46bd2b4e/gr2b_lrg.jpg)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
![Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma](https://www.spandidos-publications.com/article_images/ijo/47/2/IJO-47-02-0583-g00.jpg)
Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma
![Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma](https://www.spandidos-publications.com/article_images/ijo/47/2/IJO-47-02-0583-g03.jpg)
Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma
![Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study - The Lancet ... Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study - The Lancet ...](https://www.thelancet.com/cms/attachment/a2320fa2-cc5e-421b-95ed-3b7b3f642b1a/gr4_lrg.jpg)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study - The Lancet ...
![Frontiers | Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway) Frontiers | Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)](https://www.frontiersin.org/files/Articles/860711/fonc-13-860711-HTML/image_m/fonc-13-860711-g001.jpg)
Frontiers | Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)
![Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma - Catenacci - 2021 - The Oncologist - Wiley Online Library Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma - Catenacci - 2021 - The Oncologist - Wiley Online Library](https://theoncologist.onlinelibrary.wiley.com/cms/asset/b7f8fd2c-a221-42db-b10f-086cc1203da0/onco13907-fig-0002-m.jpg)
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma - Catenacci - 2021 - The Oncologist - Wiley Online Library
![Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) - Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) - Hye Sook Han, Bum Jun Kim, Hee-Jung Jee,](https://journals.sagepub.com/cms/10.1177/17588359211042812/asset/images/large/10.1177_17588359211042812-fig2.jpeg)
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) - Hye Sook Han, Bum Jun Kim, Hee-Jung Jee,
![JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis](https://www.mdpi.com/jcm/jcm-12-00704/article_deploy/html/images/jcm-12-00704-g005-550.jpg)
JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis
![JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis](https://www.mdpi.com/jcm/jcm-12-00704/article_deploy/html/images/jcm-12-00704-g006-550.jpg)
JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis
![Effects of an Alkalization Therapy on Nivolumab in Esophagogastric Junction Adenocarcinoma: A Case Report | PDF Effects of an Alkalization Therapy on Nivolumab in Esophagogastric Junction Adenocarcinoma: A Case Report | PDF](https://cdn.slidesharecdn.com/ss_thumbnails/10vermorkenovariancancer-110414094024-phpapp02-thumbnail.jpg?width=600&height=600&fit=bounds)
Effects of an Alkalization Therapy on Nivolumab in Esophagogastric Junction Adenocarcinoma: A Case Report | PDF
![Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort | Oncogene Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort | Oncogene](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fonc.2016.283/MediaObjects/41388_2017_Article_BFonc2016283_Fig1_HTML.jpg)
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort | Oncogene
![IJERPH | Free Full-Text | Challenges and Suggestions in the Management of Stomach and Colorectal Cancer in Uzbekistan: The Third Report of the Uzbekistan–Korea Oncology Consortium IJERPH | Free Full-Text | Challenges and Suggestions in the Management of Stomach and Colorectal Cancer in Uzbekistan: The Third Report of the Uzbekistan–Korea Oncology Consortium](https://www.mdpi.com/ijerph/ijerph-20-05477/article_deploy/html/images/ijerph-20-05477-g001.png)
IJERPH | Free Full-Text | Challenges and Suggestions in the Management of Stomach and Colorectal Cancer in Uzbekistan: The Third Report of the Uzbekistan–Korea Oncology Consortium
![Cancers | Free Full-Text | Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond Cancers | Free Full-Text | Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond](https://www.mdpi.com/cancers/cancers-14-01408/article_deploy/html/images/cancers-14-01408-g001.png)
Cancers | Free Full-Text | Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
![Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) - Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) - Hye Sook Han, Bum Jun Kim, Hee-Jung Jee,](https://journals.sagepub.com/cms/10.1177/17588359211042812/asset/images/large/10.1177_17588359211042812-fig1.jpeg)
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16) - Hye Sook Han, Bum Jun Kim, Hee-Jung Jee,
![Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma](https://www.spandidos-publications.com/article_images/ijo/47/2/IJO-47-02-0583-g04.jpg)
Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma
![JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis](https://www.mdpi.com/jcm/jcm-12-00704/article_deploy/html/images/jcm-12-00704-g004-550.jpg)
JCM | Free Full-Text | Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis
![Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial - The Lancet Oncology Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/75bee1b0-c9fa-4b67-a300-9c54cee9ac0d/gr4_lrg.jpg)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial - The Lancet Oncology
![Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort | Oncogene Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort | Oncogene](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fonc.2016.283/MediaObjects/41388_2017_Article_BFonc2016283_Fig4_HTML.jpg)
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort | Oncogene
![03 - Puma Future Rider Cut-out Wns Women Lifestyle Sneakers New - PUMA Suede Translucent White/Black Skate Shoes 383894 03 - Puma Future Rider Cut-out Wns Women Lifestyle Sneakers New - PUMA Suede Translucent White/Black Skate Shoes 383894](https://www.thenextsole.com/storage/images/383894-03.png)
03 - Puma Future Rider Cut-out Wns Women Lifestyle Sneakers New - PUMA Suede Translucent White/Black Skate Shoes 383894
![Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from](https://www.thelancet.com/cms/attachment/7dbbb513-fc18-42a8-a5dd-a104f8e31c82/gr1_lrg.jpg)